Agios Stops Tebapivat for LR-MDS – But It’s Still Moving Forward for Sickle Cell Disease
Agios scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good.
/ 352 items
#XY Event-Driven Stocks↓
Activist Investor Echo Lake Capital Launches Takeover Bid for Crashing Aclarion Stock
Echo Lake offers $4/share to buy Aclarion, plus profit rights; says company is undervalued and wants reply by June 4, 2026.
Teladoc Health Partners with Walmart to Offer Virtual Doctor Visits
Teladoc Health and Walmart launch cheap virtual care for urgent, skin, and nutrition needs via Walmart app.
TD Cowen & Evercore ISI Praise “Compelling” EDIT-401 Data as Editas Eyes 2026 Human Trials
Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.
Biohaven Shares Surge as New Drugs Deliver Breakthrough Results in Graves’ Disease and IgA Nephropathy
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
Japan Grants Orphan Drug Designation to Vanda’s Imsidolimab for Rare Skin Disease GPP
Vanda’s drug imsidolimab receives orphan drug status in Japan for the rare skin disease GPP, speeding up approval.